ライフサイエンスコーパス: unconfirmed

1 , 223 (3%) were HIV positive (including five unconfirmed).

2 82% (55% complete response/complete response-unconfirmed).

3 of long-term cardiovascular disease remains unconfirmed.

4 tive impairment, depression, and anxiety are unconfirmed.

5 n in supporting cellular photosensitivity is unconfirmed.

6 ective pH gradient at the gastric surface is unconfirmed.

7 tamine (HT)4, has been suggested but remains unconfirmed.

8 nsability and evolutionary rate has remained unconfirmed.

9 sumptions remain imprecise, unchallenged, or unconfirmed.

10 with active tuberculosis, infection is often unconfirmed.

11 The mediator(s) of TGF remains unconfirmed.

12 e is representative of the total response is unconfirmed.

13 proved technically difficult, and it remains unconfirmed.

14 ambiguous results, and these cases remained unconfirmed.

15 specific susceptibility loci are unknown or unconfirmed.

16 ence interval, 27% to 63%), but this remains unconfirmed.

17 association between the 2 disorders is still unconfirmed.

18 enin-angiotensin-dependent functions remains unconfirmed.

19 induced salt loss, but this function remains unconfirmed.

20 they are not needed, remains experimentally unconfirmed.

21 good surrogate for other dimensions remains unconfirmed.

22 tance as a risk factor for mortality remains unconfirmed.

23 care for patients but this potential remains unconfirmed.

24 their existence in dinoflagellates remained unconfirmed.

25 eved a clinical complete response (CR) or CR unconfirmed.

26 substrate import and product export is still unconfirmed.

27 ndrial changes in apoptosis in flies remains unconfirmed.

28 costeroids for treatment of bronchiolitis is unconfirmed.

29 0%, 14 complete remission/complete remission unconfirmed, 10 partial response) patients, including 17

30 tity/characteristics of such a gene(s) still unconfirmed, a lack of inactivating structural mutations

31 nalysis of variance F value=5.6, P=.001) was unconfirmed after clinical characteristic adjustment (AN

32 ved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophospha

33 %) with ROS1-positive NSCLC; one patient had unconfirmed ALK and ROS1 status.

34 sponsible for most sporadic epidemics remain unconfirmed, although attenuated vaccines that retain a

35 ed for routine cyclophosphamide treatment is unconfirmed and requires further study.

36 se; six (29%) had a complete response (three unconfirmed) and five (24%) had a partial response (one

37 7% complete response, 6.7% complete response unconfirmed, and 40% partial response).

38 er the intermediate pressure, finally to an "unconfirmed" antiferromagnetic structure under the high

39 s provide spectroscopic evidence for two yet unconfirmed As(III)-NOM interaction mechanisms, which ma

40 s sensing mechanical forces in podocytes are unconfirmed, but the classic transient receptor potentia

41 Though unconfirmed by NMR, our data suggest that the formation

42 nsitivity analyses of the true HIV status of unconfirmed cases and test sensitivity resulted in a pos

43 ll response rate, site-reported confirmed or unconfirmed complete or partial response.

44 ts (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (

45 Complete remission and unconfirmed complete remission after first-line treatmen

46 erapy to ECFI patients in complete remission/unconfirmed complete remission.

47 re as follows: 1 complete response (1.9%), 3 unconfirmed complete response (5.7%), 3 partial response

48 end point was the rate of complete response/unconfirmed complete response (CR/CRu) as assessed by an

49 iscontinuation, no complete response (CR) or unconfirmed complete response (CRu) after eight cycles,

50 If complete response (CR) or unconfirmed complete response (CRu) without evidence for

51 o received pixantrone achieved a complete or unconfirmed complete response at end of treatment compar

52 00%) with complete response (CR) in 9 (41%), unconfirmed complete response in 1 (5%), and partial res

53 he proportion of patients with a complete or unconfirmed complete response in the intention-to-treat

54 sponse rate was 82% (complete response, 50%; unconfirmed complete response, 5%; partial response, 26%

55 onse rate of 77% (15% complete response, 19% unconfirmed complete response, and 43% partial) was obse

56 l response (ie, confirmed complete response, unconfirmed complete response, and partial response) at

57 of patients achieved a complete response or unconfirmed complete response.

58 s, including a 12% rate of complete response/unconfirmed complete response.

59 representative patient cohort, complete and unconfirmed complete responses after rituximab chemother

60 Non-pathogenic, unconfirmed copy number calls were detected by both plat

61 s 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) a

62 ge III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after fir

63 ne were assessed for complete response (CR), unconfirmed CR (CRu), partial response (PR), stable dise

64 An additional 4% achieved an unconfirmed CR in each group.

65 The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 9

66 3), including a 7% complete response (CR) or unconfirmed CR rate.

67 (90.8%) and 13 with B-LL (76.5%) reached CR/unconfirmed CR, including 26 with T-LL and two with B-LL

68 complete response [CR], n = 18; undocumented/unconfirmed CR, n = 6; partial response, n = 14).

69 and 87% achieved a complete response (CR) or unconfirmed CR.

70 patients in first complete remission (CR) or unconfirmed CR.

71 was 33% including 8% complete response (CR)/unconfirmed CR.

72 ieving a complete response/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype

73 es by NHL-CT criteria included three CRs, 12 unconfirmed CRs (CRus), 16 PRs, 26 with SD, four with PD

74 including 67% complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs

75 of 15 (60%) with complete responses (CRs and unconfirmed CRs).

76 atients achieved a complete response (CR)/CR unconfirmed (CRu), and 48% of patients obtained a partia

77 Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were

78 was 100% with 86% complete response (CR)/CR unconfirmed (CRu; n = 35).

79 , ORR was 49% (14% complete response [CR]/CR unconfirmed [CRu]), median TTP was 7.0 months, and media

80 inal decarboxylation, and the two previously unconfirmed dehydroalanines.

81 d patients were assessable (two patients had unconfirmed diagnoses).

82 ain radiography) diagnostic study or with an unconfirmed diagnosis of herniated nucleus pulposus, out

83 rt comprised 31% female; 40% with RA and 16% unconfirmed diagnosis.

84 identified multiple previously unreported or unconfirmed disease associations, including known CD loc

85 ) and five (24%) had a partial response (one unconfirmed); eight (38%) patients had stable disease an

86 ed genome-wide SNP associations and 89.8% of unconfirmed genome-wide indel associations.

87 de significant SNP associations and 97.6% of unconfirmed genome-wide significant indel associations.

88 This method removed 96.1% of unconfirmed genome-wide significant SNP associations and

89 pendent dataset, the method removed 90.2% of unconfirmed genome-wide SNP associations and 89.8% of un

90 Incidence rates of histologically unconfirmed HCC increased faster than those of confirmed

91 A popular but unconfirmed hypothesis to explain how the plasma is ener

92 A scan was classified unconfirmed if (68)Ga-DOTATOC PET/CT suggested a primary

93 CD was confirmed in 511 (25.9%) and was unconfirmed in 1391 (70.5%) patients; 14 patients were d

94 outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States.

95 in five patients (13.5%), complete response unconfirmed in three (8%), and partial response in 12 (3

96 ndependently confirmed in eight studies, but unconfirmed in two others, resulting in continued disput

97 jective response rate was 26% (confirmed and unconfirmed) in the 47 patients with measurable disease,

98 ber of treatments for malaria (confirmed and unconfirmed) in these older age groups was reduced by 29

99 Seven previously unconfirmed individuals tested positive for anti-MERS-Co

100 globulin M antibody negative) and those with unconfirmed infection.

101 nsoring, which results from having to censor unconfirmed locally determined progressions.

102 e immunophenotypic and recently proposed but unconfirmed molecular biomarkers in Sezary syndrome were

103 ritize and experimentally test a set of rare unconfirmed mutations in the epidermal growth factor rec

104 LL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient h

105 urative intent, but many of these claims are unconfirmed or conflicting.

106 o have WNV infection, and the remainder were unconfirmed or determined to have false-positive results

107 Evidence of clinical activity (conventional, unconfirmed, or immune-related response or stable diseas

108 the relatedness of which would have remained unconfirmed otherwise.

109 d one durable complete response (CR) and one unconfirmed partial response (PR) in two patients with E

110 nfirmed partial response in 14 (32%), and an unconfirmed partial response in nine (20%).

111 An additional 31 (50%) had an unconfirmed partial response or stable disease as best r

112 o had received previous BRAF inhibition, one unconfirmed partial response was recorded.

113 lterations, four confirmed responses and one unconfirmed partial response were observed in patients w

114 23 confirmed partial responses (51.1%), two unconfirmed partial responses (4.4%), 14 patients with s

115 (43%) had stable disease (four of these were unconfirmed partial responses), 36 (47%) had progressive

116 plete response, three partial responses, two unconfirmed partial responses, and 22 (30%) patients rem

117 Two further patients had unconfirmed partial responses.

118 reveals approximately 500 new or previously unconfirmed plant mitochondrial proteins and outlines a

119 The questionable relevance of unconfirmed positive stool antigen CIDT results was supp

120 (19%) children with one sample, 70 (4%) were unconfirmed positive.

121 ee confirmed partial responses (PRs) and one unconfirmed PR for an overall response probability of 9%

122 nd that the data contradict the authors' own unconfirmed previous results.

123 There was one confirmed PR and two unconfirmed PRs.

124 ed quality), III (promising quality), or IV (unconfirmed quality).

125 ositive, false-positive, false-negative, and unconfirmed rates for unknown primary tumor were 38%, 7%

126 lue for syphilis associated with an isolated unconfirmed reactive treponemal chemiluminescence assay

127 ous solid tumours, with partial confirmed or unconfirmed responses in four (8%) of 53 patients; 30 (5

128 given of patients with fatal, serologically unconfirmed RMSF for whom a diagnosis of RMSF was establ

129 The associations were stronger for unconfirmed self-reported events than end points that we

130 ata on all subjects for whom vital status is unconfirmed should be sent to the SSA.

131 Although unconfirmed, the data suggest that genetic associations

132 Alternatively, consistent with a previously unconfirmed third hypothesis, the mycosamine sugar is st

133 med primary brain tumors (and a possible but unconfirmed third) were found, demonstrating a prevalenc

134 Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 patients (72.7%) an

135 A designation of complete response/unconfirmed was adopted to include patients with a great

136 ber of treatments for malaria (confirmed and unconfirmed) was observed in children.

137 The ORR was 28% (7.5% CR/CR unconfirmed) with rapid time to response (median, 2.2 mo

138 Unconfirmed work has once more indicated that a viral in